Panbela Therapeutics Inc (PBLA)

Panbela Therapeutics Inc (PBLA) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $14,564; returns 1 day -90.0%.

Panbela Therapeutics, Inc. (PBLA), based in Minneapolis, Minnesota, is a clinical-stage biopharmaceutical company that focuses on creating first-in-class therapies by modulating polyamine metabolism to treat aggressive cancers. Their lead investigational compound, SBP-101 (Ivospemin), is a stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels.

Groups PBLA belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Cancer Therapeutics
• Healthcare
• Biopharmaceutical
• Clinical Stage
• Pancreatic Cancer
• Hematologic Malignancies
• Drug Discovery
• Life Sciences

PBLA financial model: income statement, cash flow and balance sheet